| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1756 | 2018 |
| Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ... JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019 | 324 | 2019 |
| Targeting the PI3K-AKT-mTOR signaling network in cancer KH Khan, TA Yap, L Yan, D Cunningham Chinese journal of cancer 32 (5), 253, 2013 | 242 | 2013 |
| Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, ... Cancer cell 36 (1), 35-50. e9, 2019 | 240 | 2019 |
| Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial KH Khan, D Cunningham, B Werner, G Vlachogiannis, I Spiteri, T Heide, ... Cancer discovery 8 (10), 1270-1285, 2018 | 238 | 2018 |
| Cancer therapeutics: Targeting the apoptotic pathway KH Khan, M Blanco-Codesido, LR Molife Critical reviews in oncology/hematology 90 (3), 200-219, 2014 | 194 | 2014 |
| Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ S Rao, MG Guren, K Khan, G Brown, AG Renehan, SE Steigen, ... Annals of Oncology 32 (9), 1087-1100, 2021 | 180 | 2021 |
| Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, ... Clinical Cancer Research 21 (4), 739-748, 2015 | 146 | 2015 |
| Challenges in the treatment of gastric cancer in the older patient N Joharatnam-Hogan, KK Shiu, K Khan Cancer treatment reviews 85, 101980, 2020 | 127 | 2020 |
| MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma A Lampis, P Carotenuto, G Vlachogiannis, L Cascione, S Hedayat, ... Gastroenterology 154 (4), 1066-1079. e5, 2018 | 123 | 2018 |
| CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer … R Gonzalez-Exposito, M Semiannikova, B Griffiths, K Khan, LJ Barber, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 95 | 2019 |
| Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study K Khan, M Rata, D Cunningham, DM Koh, N Tunariu, JC Hahne, ... Gut 67 (8), 1484-1492, 2018 | 81 | 2018 |
| Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? K Khan, A Wale, G Brown, I Chau World Journal of Gastroenterology: WJG 20 (35), 12391, 2014 | 78 | 2014 |
| FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience SY Moorcraft, K Khan, C Peckitt, D Watkins, S Rao, D Cunningham, ... Clinical colorectal cancer 13 (4), 232-238, 2014 | 72 | 2014 |
| Targeting EGFR pathway in metastatic colorectal cancer-tumour heterogeniety and convergent evolution K Khan, N Valeri, C Dearman, S Rao, D Watkins, N Starling, I Chau, ... Critical reviews in oncology/hematology 143, 153-163, 2019 | 70 | 2019 |
| Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and … MLR Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U The Oncologist, 2016 | 68 | 2016 |
| Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives M Abdul-Latif, K Townsend, C Dearman, KK Shiu, K Khan Cancer Treatment Reviews 88, 102030, 2020 | 67 | 2020 |
| Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery Journal of British Surgery 107 (2), e161-e169, 2020 | 61 | 2020 |
| Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors SJ Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA ... Clin Cancer Res., 2014 | 53* | 2014 |
| miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial K Khan, D Cunningham, C Peckitt, S Barton, D Tait, M Hawkins, ... Oncotarget 7 (11), 12672, 2016 | 46 | 2016 |
David CunninghamThe Royal Marsden NHS Foundation Trustrmh.nhs.uk의 이메일 확인됨
David CunninghamThe Royal Marsden NHS Foundation Trustrmh.nhs.uk의 이메일 확인됨